Pfizer’s COVID-19 Vaccine Booster Shows Strong Immune Response in Children

Pfizer and BioNTech have released promising data from a phase 2/3 study on children aged five to 11 years who received a booster dose of their COVID-19 vaccine.

The companies reported a 36-fold increase in neutralizing antibodies in the 140 participants who received the booster doses approximately six months after receiving their second COVID-19 vaccine dose. And after one month, there was a six-fold increase in neutralizing antibodies against the SARS-CoV-2 wild-type strain in participants who receive the booster compared with one month after receiving the second vaccine dose.

Pfizer and BioNTech are expected to file for an FDA Emergency Use Authorization for a booster dose for this age group within days.